Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin secretagogues.

Melanie J Davies1

  • 1Department of Diabetes, Endocrinology and Cardiovascular Medicine, University Hospital of Leicester, UK. MDavies@uhl.trent.nhs.uk

Current Medical Research and Opinion
|October 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can obesity pharmacotherapy be used to manage male infertility?

Nature reviews. Endocrinology·2025
Same author

Redefining obesity: beyond body mass index.

European heart journal·2025
Same author

Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study).

Metabolites·2025
Same author

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

The New England journal of medicine·2025
Same author

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

The New England journal of medicine·2025
Same author

Use, Usability, and Experience Testing of a Digital Health Intervention to Support Chronic Kidney Disease Self-Management: Mixed Methods Study.

Journal of medical Internet research·2025
Same journal

Treatment patterns among pediatric and adult patients with ulcerative colitis in the United States: a retrospective cohort study.

Current medical research and opinion·2026
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
See all related articles

New insulin secretagogues like repaglinide and nateglinide offer improved glycemic control for type 2 diabetes patients. They present a lower risk of hypoglycemia and weight gain compared to older sulfonylureas.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Existing oral insulin secretagogues (sulfonylureas) are linked to adverse effects like hypoglycemia, weight gain, and declining beta-cell function in type 2 diabetes.
  • These agents often fail to provide durable glycemic control.

Purpose of the Study:

  • To evaluate newer insulin secretagogues, repaglinide and nateglinide, as alternatives to sulfonylureas for managing type 2 diabetes.
  • To assess their efficacy, safety profile, and potential for early intervention.

Main Methods:

  • Review of existing data on repaglinide and nateglinide.
  • Comparison of their clinical outcomes (glycemic control, HbA1c, hypoglycemia, weight changes) with sulfonylureas.
  • Exploration of combination therapy potential.

Related Experiment Videos

Main Results:

  • Repaglinide demonstrated lower hypoglycemia risk, better glycemic control, weight loss, and improved quality of life compared to sulfonylureas.
  • Nateglinide showed efficacy in lowering HbA1c with low hypoglycemia risk and potential for less weight gain, particularly in early disease stages or impaired glucose tolerance.
  • Early data suggests effective combination therapy with isophane insulin and metformin.

Conclusions:

  • Repaglinide and nateglinide represent promising alternatives to sulfonylureas for type 2 diabetes management.
  • Their favorable profiles suggest potential for early intervention and improved patient outcomes.
  • Further research is needed to validate these early findings, especially for nateglinide in specific patient populations.